Skip to main content

Raymond K. Cross, MD

Academic Title:

Professor

Primary Appointment:

Medicine

Additional Title:

Director, Inflammatory Bowel Disease Program Co-Director, Digestive Health Center

Location:

MSTF, Suite 8-00

Phone (Primary):

(410) 706-3387 (office)

Fax:

(410) 706-4330

Education and Training

Dr. Cross received his undergraduate degree from Washington and Jefferson College in Washington, Pennsylvania, and his medical degree from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania. He completed his postgraduate training in Internal Medicine at the University of Maryland and Baltimore VA Medical Centers in Baltimore, Maryland, where he was chosen as Chief Resident. He performed his Gastroenterology fellowship also at the University of Maryland and Baltimore VA Medical Centers in Baltimore. In addition, Dr. Cross has obtained a Master of Science degree in Clinical Research at the University of Maryland School of Medicine, Department of Epidemiology and Preventive Medicine, in Baltimore. 

Biosketch

Raymond K. Cross, D, MS, AGAF, FACG is a professor of medicine, Division of Gastroenterology and Hepatology at the University of Maryland, Baltimore. He is also director of the Inflammatory Bowel Disease Program at the University of Maryland School of Medicine and is co-director of the Digestive Health Center at the University of Maryland Medical Center. 

Dr. Cross received his undergraduate degree from Washington and Jefferson College and his medical degree from the University of Pittsburgh School of Medicine. He completed his postgraduate training in Internal Medicine and Gastroenterology at the University of Maryland and Baltimore VA Medical Center. In addition, Dr. Cross obtained a Master of Science degree in Clinical Research at the University of Maryland School of Medicine. 

Dr. Cross has authored over 100 journal articles, reviews, and book chapters. His research interests include application of telemedicine in the care of patients with IBD, disparities, outcomes research and clinical trials. He is Co-Chair of the Clinical Research Alliance, past Chair of the Clinical Awards Committee and Patient Education Committee, and was recently selected as vanguard site investigator for SPARC IBD for the Crohn’s and Colitis Foundation.

Research/Clinical Keywords

Outcomes research, clinical trials, telemedicine to improve care in patients with inflammatory bowel disease (IBD)

Highlighted Publications

 

  1. Cross RK, Wilson, KT, and Binion, DG. Polypharmacy and Crohn's disease. Aliment Pharmacol Ther 2005;21:1211-6
  2. Cross RK, Wilson, KT, and Binion, DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol 2005;100(10):2225-9.
  3. Cross RK, Jung, C, Wasan, S, Joshi, G, Sawyer, R, and Roghmann, MC. Racial Differences in Disease Phenotypes in Patients With Crohn's Disease. Inflamm Bowel Dis 2006;12(3):192-198.
  4. Flasar, MH, Johnson, T, Roghmann, MC, and Cross, RK. Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: A retrospective cohort study. Inflamm Bowel Dis. 2008;14(1):13-9
  5. Flasar, M, Quezada, S, Bijpuria, P, Wu, Roger, and Cross, RK. Racial Differences in Extent, Severity, and Extraintestinal Manifestations in Patients with Ulcerative Colitis: A Retrospective Cohort Study. Dig Dis Sci. 2008;53(10):2754-2760.
  6. Cross R and Finkelstein, J. Challenges in the design of a Home Telemanagement Trial for patients with ulcerative colitis. Clin Trials 2009;6(6)649-57.
  7. Samimi, R, Flasar, MH, Kavic, S, Tracy, K, and Cross, RK. Outcome of Medical Treatment of Stricturing and Penetrating Crohn’s Disease: A Retrospective Study. Inflamm Bowel Dis. 2010;16(7):1187-1194.
  8. Cross, RK, Cheevers, N, Rustgi, A, Langenberg, P, and Finkelstein, J. A Randomized, Controlled Trial of Home Telemanagement in Patients with Ulcerative Colitis (UC HAT). Inflamm Bowel Dis 2012;18(6):1018-1025.
  9. Patil, SA, Rustgi, A, Quezada, SM, Flasar, MH, Vandermeer, F, and Cross RK. Anti-TNF Therapy is Associated with Decreased Imaging and Radiation Exposure in Patients with Crohn’s Disease. Inflamm Bowel Dis. 2013;19(1):92-98.
  10. Quezada, SM and Cross, RK. Association of Age at Diagnosis and Ulcerative Colitis Phenotype. Dig Dis Sci. 2012;57(9):2402-2407.
  11. Quezada, SM, Steinberger, EK, and Cross, RK. Association of Age at Diagnosis and Crohn’s Disease Phenotype. Age Ageing. August 2012;0:1-4.
  12. Syed, A, Cross, RK, and Flasar, MH. Anti-Tumor Necrosis Factor Therapy is Associated with Infections after Abdominal Surgery in Crohn’s Disease Patients. Am J Gastroenterol. 2013;108(4):583-593.
  13. Ghazi, LJ, Lydecker, AD, Patil, SA, Rustgi, A, Cross, RK, and Flasar, MH. Racial Differences in Disease Activity and Quality of Life in Patients with Crohn’s Disease. Dig Dis Sci. 2014;50(10):2508-2513.
  14. Cross, RK, Jambaulikar, Guruprasad, Langenberg, P, Tracy, JK, Collins, JF, Katz, J, Regueiro, M, Schwartz, DA, and Quinn, CC. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and Implementation of Randomized Clinical Trial. Contemp Clin Trials. 2015;132:132-44.
  15. Huang, C, Haritunians, T, Okou, DT, Cutler, DJ, Zwick, ME, Taylor, KD, Datta, LW, Maranville, JC, Alexander, JS, Baldassano, RN, Cho, JH, Cross, RK, Dassopoulus, T, Dhere, TA, Duerr, RH, Hanson, JS, Hou, JK, Hussain, SZ, Isaacs, KL, Kachelries, KE, Kader, H, Kappelman, M, Katz, J, Kirschner, BS, Kummerle, JF, Kumar, A, Kwon, JH, Lazarev, M, Mannon, P, Moulton, DE, Osuntokun, BO, Patel, A, Rioux, JD, Rotter, JI, Saeed, S, Scherl, EJ, Silverberg, MS, Silverman, A, Targan, SR, Valentine, J, Wang, M, Zonca, M, Simpson, CL, Bridges, SL, Kimberly, RP, Rich, SS, Di Rienzo, A, Kao, LWH, McGovern, DPB, Brant, SR, and Kugathasan, S. Characterization of genetic loci that affect suspectibility to inflammatory bowel disease in African Americans. Gastroenterology. 2015; 149(6): 1575-86.
  16. Flasar, M, Chao, J, Ozbay, AB, Skup, M, Lu, M, and Cross, R. Biological and Immunomodulator Use in Crohn’s Disease in a Medicaid Population. Inflamm Bowel Dis. 2016; 22(5): 1056-64.
  17. Rajan, D, Greer, JB, Regueiro, MD, Baidoo, L, Binion, DG, Herfarth, HH, Siegel, CA, Hartman, DJ, Farraye, FA, Koutrabakis, IE, Brand, MH, Williams, ED, Goyal, A, and Cross, RK. IBD LIVE Case Series-Case 6: Persistent Skin Lesions in a Patient with Crohn’s Disease: You Hear Hoof Beats and Discover a Zebra. Inflamm Bowel Dis. 2016; 22(11): 2754-2764.
  18. Brant, SR, Okou, DT, Simpson, CL, Cutler, DJ, Haritunians, T, Bradfield, JP, Chopra, P, Prince, J, Begum, F, Kumar, A, Huang, C, Venkateswaran, S, Wei, Z, Thomas, K, Herrington, L, Klapproth, JA, Quiros, A, Liu, Z, Alexander, JS, Baldassano, RN, Dudley-Brown, S, Cross, RK, Dassopoulos, T, Dhere, TA, Dryden, GT, Hanson, JS, Hou, JK, Hussain, SZ, Denson, LA, Hyams, J, Mack, D, Isaacs, KL, Kader, H, Kappelman, MD, Katz, J, Kellermayer, R, Kirschner, BS, Kuemmerle, JF, Kwon, JH, Li, E, Mannon, P, Moulton, DE, Newberry, RD, Osuntokun, BO, Patel, A, Saeed, S, Targan, SR, Valentine, J, Wang, M, Lazarev, M, Zonca, M, Datta, LW, Rioux, JD, Duerr, RH, Silverberg, MS, Cho, JH, Hakonarson, H, Zwick, ME, McGovern, DPB, Kugathasan, S. Genome-wide Association Identifies African-Specific Susceptibility Loci in African Americans with Inflammatory Bowel Disease. Gastroenterology. 2017; 152(1):206-217 e202.
  19. Cross, RK and Kane, S. Integration of Telemedicine Into Clinical Gastroenterology and Hepatology. Clin Gastroenterol Hepatol. 2017; 15(2): 175-181.
  20. Allen, J, Szigethy, EM, Reiss, M, Cohen, W, Perera, LP, Brillstein, L, Cross, RK, Schwartz, DA, Kosinski, LR, Colton, JB, LaRusso, E, Atreja, A, and Regueiro, M. White Paper AGA: The Impact of Psychosocial Factors on the Care of Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2017; 15(7): 986-997.
  21. Christian, KE, Jambaulikar, GD, Hagan, MN, Syed, AM, Briscoe, JA, Brown, SA, Campbell, EV, Gadani, AB, and Cross, RK. Predictors of Early Readmission in Hospitalized Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Nov; 23(11): 1891-1897.
  22. Bertha, M, Vasantharoopan, A, Kumar, A, Bruce, B, Prince, J, Hofmekler, T, Okou, D, Chopra, P, Wang, G, Sauer, C, Landers, CJ, Hussain, SZ, Cross, RK, Baldassano, RN, Kappelman, MD, Katz, J, Alexander, JS, Kirschner, BS, Moulton, DE, Osuntokun, BO, Patel, A, Saeed, S, Klapproth, JA, Dhere, TA, Dubinskey, MC, McGovern, D, and Kugathasan, S. IBD Serology and Disease Outcomes in African-Americans with Crohn’s Disease. Inflamm Bowel Dis. 2017 Dec 19; 24(1): 209-216.
  23. Abutaleb, A, Buchwald, A, Chudy-Onwugaje, K, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, JK, Ghazi, L, Patil, SA, Quezada, SM, Russman, KM, Quinn, CC, Jambaulikar, G, Beaulieu, DB, Horst, S, and Cross, RK. Inflammatory Bowel Disease Telemedicine Clinical Trial: Impact of Weekly Educational Text Messages on Disease-Specific Knowledge Over One Year. Inflamm Bowel Dis. 2018; 24 (10): 2191-2197. https://doi.org/10.1093/ibd/izy149.
  24. Eluri, S, Cross, RK, Martin, C, Weinfurt, KP, Flynn, KE, Long, MD, Chen, W, Anton, K, Sandler, RS, and Kappelman, MD. Inflammatory Bowel Diseases Can Adversely Impact Domains of Sexual Function Such as Satisfaction with Sex Life. Dig Dis Sci. 2018; 63(6): 1572-1582.
  25. Chudy-Onwugaje, K, Abutaleb, A, Buchwald, A, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, JK, Ghazi, L, Patil, SA, Quezada, SM, Russman, KM, Horst, S, Beaulieu, DB, Quinn, CC, Jambaulikar, G, and Cross, RK. Age Modifies the Association between Depressive Symptoms and Adherence to Self-Testing with Telemedicine in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018; 24(12): 2648-2654. https://doi.org/10.1093/ibd/izy194.
  26. Dubinsky, MC, Cross, RK, Sandborn, WJ, Long, M, Song, X, Shi, N, Ding, Y, Eichner, S, Pappalardo, B, Ganguli, A, and Wang, A. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Apr 13. DOI; 10.1093/ibd/izy065.
  27. Cross, RK and Herfarth, H. Is there a role for thiopurines in IBD? Am J Gastroenterol. 2018 Aug; 113(8): 1121-1124. Doi: 10.1038/s41395-018-0175-8.
  28. Herfarth, H, Barnes, EL, Valentine, JF, Hanson, J, Higgins, PDR, Isaacs, KL, Jackson, S, Osterman, MT, Anton, K, Ivanova, A, I, Long, MD, Martin, C, Sandler, RS, Abraham, B, Cross, RK, Dryden, G, Fischer, M, Harlan, W, Levy, C, McCabe, R, Polyak, S, Saha, S, Williams, E, Yajnik, V, Hamilton, F, Serrano, J, James, S, Sands, BE and Lewis, JD. Methotrexate is not superior to placebo in maintaining steroid-free remission in ulcerative colitis. Gastro. 2018 Octo; 155(4): 1098-1108. doi: 10.1053/j.gastro.2018.06.046.
  29. Cross, RK, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, JK, Collins, JF, Katz, J, Ghazi, L, Patil, SA, Quezada, SM, Russman, K, Riaz, M, Jambaulikar, G, Sivasailam, B, and Quinn, C. A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD). Am J Gastroenterol. 2018 March; 114(3):472-482. doi: 10.1038/s41395-018-0272-8.
  30. Patil, SA, Flasar, MH, Lin, J, Lingohr-Smith, M, Skup, M, Wang, S, Chao, J, and Cross, RK. Reduced Imaging Radiation Exposure Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn’s Disease. Dig Dis Sci. 2019 Jan; 64(1): 60-67. doi: 10.1007/s10620-018-5322-y.
  31. Bilgrami, Z, Abutaleb, A, Chudy-Onwugajae, K, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, JK, Ghazi, L, Patil, SA, Quezada, SM, Russman, KM, Quinn, CC, Jambaulikar, G, Beaulieu, DB, Horst, S, and Cross, RK. Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activation and Self-Efficacy. Dig Dis Sci. 2020; 65(1): 96-103. DOI 0.1007/s10620-018-5433-5. Correction to: Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activiation and Self-Efficacy. Dig Dis Sci. 2020; 65(2): 668. 10.1007/s10620-019-05953-4
  32. Ko, CW, Singh, S, Feuerstein, JD, Falck-Ytter, C, Falck-Ytter, Y, and Cross, RK. American Gastroenterological Association Institute Guideline on the Management of Mild-to-Moderate Ulcerative Colitis. Gastro. 2019 Feb; 156(3): 748-764. doi: 10.1053/j.gastro.2018.12.009.
  33. Schad, CA, Cross, RK, Syed, A, Lonasko, S, and Bafford, AC. Early postoperative anti-TNF therapy does not increase complications following abdominal surgery in patients with Crohn’s disease. Dig Dis Sci. 2019 Jul; 64(7): 1959-1966. Doi: https://doi.org/10.1007/s10620-019-5476-2.
  34. Kinnucan, J, Binion, D, Cross, R, Evans, E, Harlen, K, Matarese, L, Mullins, A, O’Neal, B, Reiss, M, Scott, FI, Weaver, A, and Rosenberg, J. Inflammatory Bowel Disease Care System Referral Pathways. Gastro. 2019 Apr 10. pii: S0016-5085(19)35665-3. doi: 10.1053/j.gastro.2019.03.064
  35. Christian, KE, Russman, KM, Rajan, DP, Barr, EA, and Cross, RK. Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post-Hoc Analysis of Clinical Trials. Inflamm Bowel Dis. 2020; 26(1): 125-131. https://doi.org/10.1093/ibd/izz133
  36. Quinn, CC, Chard, S, Roth, EG, Eckert, JK, Russman, KM, and Cross, RK. The Telemedicine for Patients with Inflammatory Bowel Disease (TELE-IBD) Clinical Trial: Qualitative Assessment of Participants’ Perceptions. J Med Internet Res. 2019; 21(6): e14165.
  37. Scott, FI, Rubin, DT, Kugathasan, S, Bousvaros, A, Elson, CO, Newberry, RD, Melmed, GY, Pekow, J, Fleshman, JW, Boyle, BM, Mahadevan, U, Cannon, LM, Long, MD, Cross, RK, Ha, CY, Lasch, KL, Robinson, AM, Rafferty, JF, Lee, JJ, Cowden, DK, Weaver, A, Shtraizent, N, Honig, G, Hurtado-Lorenzo, A, and Heller, CA. Challenges in IBD Research: Pragmatic Clinical Research. Inflamm Bowel Dis. 2019; 25(S2): S40-47.
  38. Shen, B, Kochhar, G, Navaneethan, U, Farraye, FA, Schwartz, DA, Iacucci, M, Bernstein, CN,Dryden, G, Cross, RK, Bruining, DH, Kobayashi, T, Lukas, M, Shergill, A, Bortlik, M, Lan, N, Lukas, M, Tang, SJ, Kotze, PG, Kiran, RP, Dulai, PS, El-Hachem, S, Coelho-Prabhu, N, Thakkar, S, Mao, R,Chen, G, Zhang, S, González Suárez, B, Gonzalez Lama, Y, Silverberg, MS, Sandborn, WJ. Practical Guideline on Endoscopic Therapy of Crohn’s Disease Strictures: An Expert Consensus from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol. 2020. Published Online January 16, 2020. https://doi.org/10.1016/
    S2468-1253(19)30366-8.
  39. Schliep, M, Chudy-Onwugaje, K, Abutaleb, A, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, KT, Ghazi, L, Patil, SA, Quezada, S, Russman, K, Horst, S, Beaulieu, D, Quinn, C, Jambaulikar, G, and Cross, RK. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared to standard care at tertiary referral centers. Crohn’s & Colitis 360. 31 January 2020; 2(1).

Additional Publication Citations

  1. Cross, RK, Longhitano, JP, Rapoport, AP, Cadogan, MA, Brown, LA and Mackowiak, PA. A 78-year-old man with pancytopenia and abnormal lymphocytes. The American Journal of Medical Sciences 2001;322:151-155.
  2. Cross, RK, Longhitano, JP, Oursler, KA, Saladino, AJ, and Mackowiak, PA. A 75-year-old man with right upper quadrant pain and gallstones. The American Journal of Medical Sciences 2002;323:146-150.
  3. Cross RK, Jr. and Howell, C. Two cases of spontaneous epidural abscess in patients with cirrhosis. South Med J. 2003;96:291-293.
  4. Gobert, AP, Cheng, Y., Akhtar, M., Mersey, BD, Blumberg, DR, Cross, RK, Chaturvedi, R., Drachenberg, CB, Boucher, JL, Hacker, A., Casero, RA, Jr., and Wilson, KT. Protective role of arginase in a mouse model of colitis. J Immunol 2004;173:2109-17.
  5. Cross RK, Wilson, KT, and Binion, DG. Polypharmacy and Crohn's disease. Aliment Pharmacol Ther 2005;21:1211-6
  6. Cross RK, Wilson, KT, and Binion, DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol 2005;100(10):2225-9.
  7. Cross RK and Binion, DG. “Narcotic use in patients with Crohn’s disease: reply form Drs. Cross and Binion.” Am J Gastroenterol 2006;101(6):1397-8.
  8. Cross RK, Arora, M, and Finkelstein, J. Acceptance of telemanagement is high in patients with inflammatory bowel disease. J Clin Gastroenterol 2006;40(3):200-8.
  9. Cross RK, Jung, C, Wasan, S, Joshi, G, Sawyer, R, and Roghmann, MC. Racial Differences in Disease Phenotypes in Patients With Crohn's Disease. Inflamm Bowel Dis 2006;12(3):192-198.
  10. Castro, HK, Cross, RK, and Finkelstein, J. Using a Home Automated Telemanagement System (HAT): Experiences and Perceptions in Patients with Inflammatory Bowel Disease. AMIA Annu Symp Proc 2006;872.
  11. Cross, RK and Finkelstein, J. Feasibility and Acceptance of a Home Telemanagement System in Patients with Inflammatory Bowel Disease: A 6-Month Pilot Study. Dig Dis Sci 2007;52(2):357-364.
  12. Donovan, M, Lunney, K, Carter-Pokras, O, and Cross, RK. Prescribing Patterns and Awareness of Adverse Effects of Infliximab: A Health Survey of Gastroenterologists. Dig Dis Sci. Aug 2007;52(8):1798-1805.
  13. Dunnigan, M, Yfantis, H, Rapoport, AP, Hosseinzadeh, K, Gocke, CD, and Cross, RK. Large cell lymphoma presenting as a flare of colitis in a patient with common variable immune deficiency. Dig Dis Sci. 2007;52(3):830-4.
  14. Cross, RK, Lapshin, O, and Finkelstein, J. Patient Subjective Assessment of Drug Side Effects in Inflammatory Bowel Disease. J Clin Gastroenterol. 2008;42(3):244-51
  15. Flasar, MH, Johnson, T, Roghmann, MC, and Cross, RK. Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: A retrospective cohort study. Inflamm Bowel Dis. 2008;14(1):13-9
  16. Flasar, M, Quezada, S, Bijpuria, P, Wu, Roger, and Cross, RK. Racial Differences in Extent, Severity, and Extraintestinal Manifestations in Patients with Ulcerative Colitis: A Retrospective Cohort Study. Dig Dis Sci. 2008;53(10):2754-2760
  17. Greenberg, R, Greenwald, B, Ioffe, O, Roth, S, and Cross, RK. Squamous Dysplasia of the Rectum in a Patient with Ulcerative Colitis Treated with 6-Mercaptopurine. Dig Dis Sci. 2008;53(3):760-4.
  18. Flasar, M, Roghmann, MC, and Cross, RK. “Disparities in IBD Care: Time to Correct a Problem: reply from Drs. Flasar, Roghmann, and Cross.” Gastroenterology. 2008;134(5):1618-1619.
  19. Cross, RK. Another Anti-TNF Therapy for Patients with Crohn’s Disease (Summary of Schreiber, S, Khaliq-Kareemi, M, Lawrance, IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s Disease. N Eng J Med.
  20. 2007;357:239-250). Inflamm Bowel Dis. 2008;14(3):425-427.
  21. Warren, JW, Howard, FM, Cross, RK, Good, J, Weissman, M, Wesselmann, U, Langenberg, P, Greenberg, P, and Clauw, D. “Antecedent non-bladder syndromes in a case control study of interstitial cystitis/painful bladder syndrome”. Urology. 2009;73(1):52-7.
  22. Quezada, S, Turner, P, Alexiev, B, Daly, B, and Cross, RK. “Severe Refractory Orofacial Crohn’s Disease: Report of a Case”. Dig Dis Sci 2009;54(10):2290-5.
  23. Cross, RK, Cheevers, N, and Finkelstein, J. Home Telemanagement for Patients with Ulcerative Colitis (UC HAT). Dig Dis Sci 2009;54(11):2463-2472.
  24. St. Charles, M, Weiss Smith, SR, Beardsley, R, Fedder, DO, Carter-Pokras, O, and Cross, RK. Gastroenterologists Prescribing of Infliximab: A National Survey. Inflamm Bowel Dis. 2009;15(10)1467-75.
  25. Cross R and Finkelstein, J. Challenges in the design of a Home Telemanagement Trial for patients with ulcerative colitis. Clin Trials 2009;6(6)649-57.
  26. Ghazi, L and Cross, RK. Fever of Unknown Origin in an Immune Suppressed Patient with Crohn’s Disease: An Unusual Cause. Practical Gastroenterology 2010;34(11):42-46.
  27. Samimi, R, Flasar, MH, Kavic, S, Tracy, K, and Cross, RK. Outcome of Medical Treatment of Stricturing and Penetrating Crohn’s Disease: A Retrospective Study. Inflamm Bowel Dis. 2010;16(7):1187-1194.
  28. Cross, RK, Cheevers, N, Rustgi, A, Langenberg, P, and Finkelstein, J. A Randomized, Controlled Trial of Home Telemanagement in Patients with Ulcerative Colitis (UC HAT). Inflamm Bowel Dis 2012;18(6):1018-1025.
  29. Cross, RK. Application of Telemedicine for Inflammatory Bowel Disease: Review of the Literature and Future Implications. J Gastrointest Digest Sys. October 2011;1(e102).
  30. Flasar, MH, Cross, RK, and Doman, DB. Current and Future Role of Ulcerative Colitis Serogenomics. Gastroenterology and Hepatology. November 2011;7(11):720-727.
  31. Patil, SA, Rustgi, A, Quezada, SM, Flasar, MH, Vandermeer, F, and Cross RK. Anti-TNF Therapy is Associated with Decreased Imaging and Radiation Exposure in Patients with Crohn’s Disease. Inflamm Bowel Dis. 2013;19(1):92-98.
  32. Quezada, SM and Cross, RK. Association of Age at Diagnosis and Ulcerative Colitis Phenotype. Dig Dis Sci. 2012;57(9):2402-2407.
  33. Faust, AH, Halpern, LF, Danoff-Burg, S, and Cross, RK. Psychosocial Factors Contributing to Inflammatory Bowel Disease Activity and Health-Related Quality of Life. Gastroenterology & Hepatology. March 2012;8(3):1-9.
  34. McLean, LP, Shea-Donahue, T, and Cross, RK. Vedolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease. Immunotherapy. 2012;4(9):883-898.
  35. Patil, S and Cross, RK. Where We’re Going, We Don’t Need Appointments: the Future of Telemedicine in IBD. (Summary of Krier, M, Kaltenbach, T, McQuaid, K, et al. Potential Us of telemedicine to provide outpatient care for inflammatory bowel disease. Am J Gastroenterol. 2011;106:2063-7). Inflamm Bowel Dis. 2012;18(11):2199-2200.
  36. Quezada, SM, Steinberger, EK, and Cross, RK. Association of Age at Diagnosis and Crohn’s Disease Phenotype. Age Ageing. August 2012;0:1-4.
  37. Patil, SA, Rustgi, A, Langenberg, P, and Cross, RK. Comparative Effectiveness of Anti-TNF Agents for Crohn’s Disease in a Tertiary Referral IBD Practice. Dig Dis Sci. 2013;58(1):209-215.
  38. Ghazi, LJ, Patil, SA, Rustgi, A, Flasar, MH, Razeghi, S, and Cross, RK. Step Up versus Early Biologic Therapy for Crohn’s Disease in Clinical Practice. Inflamm Bowel Dis. 2013;19(7):1397-1403.
  39. Syed, A, Cross, RK, and Flasar, MH. Anti-Tumor Necrosis Factor Therapy is Associated with Infections after Abdominal Surgery in Crohn’s Disease Patients. Am J Gastroenterol. 2013;108(4):583-593.
  40. Quezada, SM and Cross, RK. To Yeast or Not to Yeast: A Probiotic Question. (Summary of Bourreille, A, Cadiot, G, Le Dreau, G, et al. Saccharomyces Boulardii for the Prevention of Relapse in Crohn’s Disease: Results of a Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial. Clin Gastroenterol Hepatol). Clin Gastroenterol Hepatol. 2013;11(8): 988-990.
  41. McLean, LP, Cross, RK, and Shea-Donohue, T. Combined Blockade of IL-17A and IL-17F Prevents the Development of Experimental Colitis. (Summary of Wedebye Schmidt, EG, Larsen, HL, Kristensen, N et al. TH17 Cell Induction and Effects of IL-17A and IL-17F Blockade in Experimental Colitis. Inflamm Bowel Dis). Immunotherapy. 2013;5(9):1-3.
  42. Razeghi, S, Halvorson, CR, Gaspari, AA, and Cross, RK. Successful Treatment of Localized Pyoderma Faciale in a Patient with Crohn’s Disease. Gastroenterology & Hepatology. 2013;9(8):541-544.
  43. Cheng, FF, McLean, LP, and Cross, RK. What is the Role of Vedolizumab in the Era of Anti-TNF Agents. (Summary of Sandborn, WJ, Feagan, BG, and Rutgeerts, P et al. Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med). Ann Transl Med. 2014;2(1):1-4.
  44. Flasar, M, Syed, A, and Cross, RK. “Letter to the Editor Kotze et al.: reply from Dr. Flasar, Mr. Syed, and Dr. Cross.” Am J Gastroenterol. 2014;109(1):139-140.
  45. McLean, LP, Chun, J, and Cross, RK. “Right Lower Quadrant Pain in a Patient with IBD of Undetermined Type”. Clin Gastroenterol and Hepatol. 2014;12(4):A29-30.
  46. McLean, LP and Cross, RK. “Adverse Events in IBD: To Stop or Continue Immune Suppressant and Biologic Treatment”. Expert Rev Gastroenterol Hepatol. 2014;8(3):223-240.
  47. Patil, SA and Cross, RK. “Can You Hear Me Now? Frequent Telephone Encounters for Management of Patients with Inflammatory Bowel Disease. (Summary of Ramos-Rivers, CM, Regueiro, M, Vargas, EJ et al. Association Between Telephone Activity and Features of Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol). Clin Gastroenterol Hepatol. 2014;12(6):995-996.
  48. Ghazi, LJ, Lydecker, AD, Patil, SA, Rustgi, A, Cross, RK, and Flasar, MH. Racial Differences in Disease Activity and Quality of Life in Patients with Crohn’s Disease. Dig Dis Sci. 2014;50(10):2508-2513.
  49. Osterman, MT, Aberra, FN, Cross, R, Liakos, S, McCabe, R, Shafran, I, Wolf, D, Hardi, R, Nessel, L, Brensinger, C, Gilroy, E, and Lewis, JD. A Randomized Controlled Trial of Mesalamine Dose Escalation for Ulcerative Colitis in Remission. Clin Gastroenterol Hepatol. 2014;12(11):1887-93.
  50. Flasar, MH and Cross, RK. What is the need for comparative effectiveness studies in IBD? Expert Rev Gastroenterol Hepatol. Early online, 2014;8(8):851-4.
  51. Zullow, S, Flasar, MH, Greenberg, D, Tracy, JK, Rustgi, A, and Cross, RK. A Health Survey of Gastroenterologist Prescribing Practices of Adalimumab for Treatment of Crohn’s Disease: Final Results. Gastroenterology & Hepatology. 2014;10(8):1-7.
  52. Regueiro, MD, Greer, JB, Binion, DG, Schraut, WH, Goyal, A, Keilo, DJ, Cross, RK, Williams, ED, Herfarth, HH, Siegel, CA, Oikonomou, I, Brand, MH, Hartman, DJ, Tublin, ME, Davis, PL, Baidoo, L, Szigethy, E, and Watson, AR. The Inflammatory Bowel Disease Live Interinstitutional and Interdisciplinary Videoconference Education (IBD LIVE) Series. Inflamm Bowel Dis. 2014;20(10):1687-95.
  53. Ghazi, LJ and Cross, RK. The Role of Telemedicine and E-Health in the Management of Inflammatory Bowel Disease: Improving Patient Outcomes. Smart Homecare Technology and Telehealth. 2015;3:17-24.
  54. Quezada, SM, Rustgi, A, Jambaulikar, GD, and Cross, RK. Differential Response to Microbial Antigens by Age of Diagnosis in Patients with Crohn’s Disease. Clin Exp Gastroenterol. 2015;8:169-74.
  55. Le, P, Greer, J, Oikonomou, I, Schraut, W, Siegel, C, Cross, RK, Holubar, S, Tinsley, A, Koltun, W, Binion, D, Regueiro, M. Previous Cancer in a Patient with Crohn’s Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment? Inflamm Bowel Dis. 2015; 21(6): 1401-6.
  56. Cross, RK, Jambaulikar, Guruprasad, Langenberg, P, Tracy, JK, Collins, JF, Katz, J, Regueiro, M, Schwartz, DA, and Quinn, CC. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and Implementation of Randomized Clinical Trial. Contemp Clin Trials. 2015;132:132-44.
  57. George, LA, Gadani, A, Cross, RK, Jambaulikar, G, and Ghazi, LJ. Psoriasiform Skin Lesions are Caused by Anti-TNF Agents used for the Treatment of Inflammatory Bowel Disease. Dig Dis Sci. 2015; 60(11): 3424-30.
  58. Hagan, M and Cross, RK. Vedolizumab for Treating Crohn’s Disease and Ulcerative Colitis. Expert Opin Drug Saf. 2015; 14(9): 1-8
  59. Huang, C, Haritunians, T, Okou, DT, Cutler, DJ, Zwick, ME, Taylor, KD, Datta, LW, Maranville, JC, Alexander, JS, Baldassano, RN, Cho, JH, Cross, RK, Dassopoulus, T, Dhere, TA, Duerr, RH, Hanson, JS, Hou, JK, Hussain, SZ, Isaacs, KL, Kachelries, KE, Kader, H, Kappelman, M, Katz, J, Kirschner, BS, Kummerle, JF, Kumar, A, Kwon, JH, Lazarev, M, Mannon, P, Moulton, DE, Osuntokun, BO, Patel, A, Rioux, JD, Rotter, JI, Saeed, S, Scherl, EJ, Silverberg, MS, Silverman, A, Targan, SR, Valentine, J, Wang, M, Zonca, M, Simpson, CL, Bridges, SL, Kimberly, RP, Rich, SS, Di Rienzo, A, Kao, LWH, McGovern, DPB, Brant, SR, and Kugathasan, S. Characterization of genetic loci that affect suspectibility to inflammatory bowel disease in African Americans. Gastroenterology. 2015; 149(6): 1575-86.
  60. Cross, RK. Which patients with inflammatory bowel disease should receive combination therapy? Expert Rev Gastroenterol Hepatol. 2015; 9(6): 715-717.
  61. Sunseri, WM, Kugathasan, S, Keljo, DJ, Greer, JB, Ranganathan, S, Cross, RK, Siegel, CA, and Regueiro, MD. IBD LIVE Case Series-Case 3: Very Early-Onset Inflammatory Bowel Disease: When Genetic Testing Proves Beneficial. Infamm Bowel Dis. 2015; 21(12): 2958-68.
  62. Flasar, M, Chao, J, Ozbay, AB, Skup, M, Lu, M, and Cross, R. Biological and Immunomodulator Use in Crohn’s Disease in a Medicaid Population. Inflamm Bowel Dis. 2016; 22(5): 1056-64.
  63. Gulati, A, Clarke, K, Greer, J, Binion, D, Brand, M, Farraye, F, Cross, R, Baidoo, L, Schraut, W, Hartman, D, Regueiro, M. IBD Live Case Series-Case 4: Worms in IBD: Friend or Foe. Inflamm Bowel Dis. 2016; 22(6): 1462-72.
  64. McLean, LP and Cross, RK. Integrin Antagonists as Potential Therapeutic Options for the Treatment of Crohn’s Disease. Expert Opinion on Investigational Drugs. 2016; 25(3): 263-273.
  65. McLean, LP and Cross, RK. Pharmacodynamic assessment of vedolizumab for ulcerative colitis. Expert Opinion on Drug Metabolism and Toxicology. 2016; DOI: 10.1080/17425255.2016.1181171.
  66. Quezada, SM, Langenberg, P, and Cross, RK. Cigarette smoking adversely affects disease activity and disease-specific quality of life in patients with Crohn’s disease at a tertiary referral center. Clinical and Experimental Gastroenterology. 2016; 2016 (9): 307-310.
  67. Rajan, D, Greer, JB, Regueiro, MD, Baidoo, L, Binion, DG, Herfarth, HH, Siegel, CA, Hartman, DJ, Farraye, FA, Koutrabakis, IE, Brand, MH, Williams, ED, Goyal, A, and Cross, RK. IBD LIVE Case Series-Case 6: Persistent Skin Lesions in a Patient with Crohn’s Disease: You Hear Hoof Beats and Discover a Zebra. Inflamm Bowel Dis. 2016; 22(11): 2754-2764.
  68. Stidham, RW and Cross, RK. Endoscopy and cross-sectional imaging for assessing Crohn’s disease activity. Tech Gastrointest Endosc. 2016 Jul; 18(3): 123-130.
  69. Brant, SR, Okou, DT, Simpson, CL, Cutler, DJ, Haritunians, T, Bradfield, JP, Chopra, P, Prince, J, Begum, F, Kumar, A, Huang, C, Venkateswaran, S, Wei, Z, Thomas, K, Herrington, L, Klapproth, JA, Quiros, A, Liu, Z, Alexander, JS, Baldassano, RN, Dudley-Brown, S, Cross, RK, Dassopoulos, T, Dhere, TA, Dryden, GT, Hanson, JS, Hou, JK, Hussain, SZ, Denson, LA, Hyams, J, Mack, D, Isaacs, KL, Kader, H, Kappelman, MD, Katz, J, Kellermayer, R, Kirschner, BS, Kuemmerle, JF, Kwon, JH, Li, E, Mannon, P, Moulton, DE, Newberry, RD, Osuntokun, BO, Patel, A, Saeed, S, Targan, SR, Valentine, J, Wang, M, Lazarev, M, Zonca, M, Datta, LW, Rioux, JD, Duerr, RH, Silverberg, MS, Cho, JH, Hakonarson, H, Zwick, ME, McGovern, DPB, Kugathasan, S. Genome-wide Association Identifies African-Specific Susceptibility Loci in African Americans with Inflammatory Bowel Disease. Gastroenterology. 2017; 152(1):206-217 e202.
  70. Cross, RK and Kane, S. Integration of Telemedicine Into Clinical Gastroenterology and Hepatology. Clin Gastroenterol Hepatol. 2017; 15(2): 175-181.
  71. Allen, J, Szigethy, EM, Reiss, M, Cohen, W, Perera, LP, Brillstein, L, Cross, RK, Schwartz, DA, Kosinski, LR, Colton, JB, LaRusso, E, Atreja, A, and Regueiro, M. White Paper AGA: The Impact of Psychosocial Factors on the Care of Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2017; 15(7): 986-997.
  72. Zullow, S, Jambaulikar, G, Rustgi, A, Quezada, S, and Cross, RK. Risk Factors for Vitamin D Deficiency and Impact of Repletion in a Tertiary Care Inflammatory Bowel Disease Population. Dig Dis Sci. 2017 Aug; 62(8): 2072-2078.
  73. Christian, KE, Jambaulikar, GD, Hagan, MN, Syed, AM, Briscoe, JA, Brown, SA, Campbell, EV, Gadani, AB, and Cross, RK. Predictors of Early Readmission in Hospitalized Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Nov; 23(11): 1891-1897.
  74. Patil, SA and Cross, RK. Medical versus Surgical Management of Penetrating Crohn’s Disease: the Current Situation and Future Perspectives. Expert Rev Gastroenterol Hepatol. 21 Jun 2017: 1-6. http://dx.doi.org/10.1080/17474124.2017.1342536.
  75. Cross, RK. Review Article: Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild to Moderate Ulcerative Colitis. Inflamm Bowel Dis. 2017; 23(10):1689-1701.
  76. Bertha, M, Vasantharoopan, A, Kumar, A, Bruce, B, Prince, J, Hofmekler, T, Okou, D, Chopra, P, Wang, G, Sauer, C, Landers, CJ, Hussain, SZ, Cross, RK, Baldassano, RN, Kappelman, MD, Katz, J, Alexander, JS, Kirschner, BS, Moulton, DE, Osuntokun, BO, Patel, A, Saeed, S, Klapproth, JA, Dhere, TA, Dubinskey, MC, McGovern, D, and Kugathasan, S. IBD Serology and Disease Outcomes in African-Americans with Crohn’s Disease. Inflamm Bowel Dis. 2017 Dec 19; 24(1): 209-216.
  77. Wong, U and Cross, RK. Primary and Secondary Non-Response to Infliximab: Mechanisms and Countermeasures. Expert Opinion on Drug Metabolism and Toxicology. 20 Jun 2017; 10: 1-8. http://dx.doi.org/10.1080/17425255.2017.1377180.
  78. Engels, M, Cross, RK, and Long, MD. Exercise in Patients with Inflammatory Bowel Disease: Current Perspectives. Clin Exp Gastroenterol. 22 Dec 2017; 11:1-11. doi: 10.2147/CEG.S120816.
  79. Christian, K and Cross, RK. Improving Outcomes in Patients with Inflammatory Bowel Disease Through Integrated Multi-Disciplinary Care-the Future of IBD Care. Clin Gastroenterol Hepatol. 2018; 16(11): 1708-1709.
  80. Patil, SA and Cross, RK. Current Landscape of Telemedicine Practice in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018; 24(9): 1910-1917. doi.org/10.1093/ibd/izy113.
  81. Abutaleb, A, Buchwald, A, Chudy-Onwugaje, K, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, JK, Ghazi, L, Patil, SA, Quezada, SM, Russman, KM, Quinn, CC, Jambaulikar, G, Beaulieu, DB, Horst, S, and Cross, RK. Inflammatory Bowel Disease Telemedicine Clinical Trial: Impact of Weekly Educational Text Messages on Disease-Specific Knowledge Over One Year. Inflamm Bowel Dis. 2018; 24 (10): 2191-2197. https://doi.org/10.1093/ibd/izy149.
  82. Eluri, S, Cross, RK, Martin, C, Weinfurt, KP, Flynn, KE, Long, MD, Chen, W, Anton, K, Sandler, RS, and Kappelman, MD. Inflammatory Bowel Diseases Can Adversely Impact Domains of Sexual Function Such as Satisfaction with Sex Life. Dig Dis Sci. 2018; 63(6): 1572-1582.
  83. Chudy-Onwugaje, K, Abutaleb, A, Buchwald, A, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, JK, Ghazi, L, Patil, SA, Quezada, SM, Russman, KM, Horst, S, Beaulieu, DB, Quinn, CC, Jambaulikar, G, and Cross, RK. Age Modifies the Association between Depressive Symptoms and Adherence to Self-Testing with Telemedicine in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018; 24(12): 2648-2654. https://doi.org/10.1093/ibd/izy194.
  84. Proksell, SS, Greer, JB, Theisen, BK, Davis, PL, Rosh, JR, Keljo, DJ, Goyal, A, Shah, SA, Brand, MH, Herfarth, HH, Cross, RK, Siegel, CA, Kolturn, WA, Isaacs, KL, and Regueiro, MD. IBD LIVE Case Series: Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn’s Colitis? Inflamm Bowel Dis. 2018 Mar 19; 24(4): 698-713.
  85. Dubinsky, MC, Cross, RK, Sandborn, WJ, Long, M, Song, X, Shi, N, Ding, Y, Eichner, S, Pappalardo, B, Ganguli, A, and Wang, A. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Apr 13. DOI; 10.1093/ibd/izy065.
  86. Cross, RK and Herfarth, H. Is there a role for thiopurines in IBD? Am J Gastroenterol. 2018 Aug; 113(8): 1121-1124. Doi: 10.1038/s41395-018-0175-8.
  87. Patil, SA and Cross, RK. More skin in the game: Screening for skin cancer in IBD patients. Dig Dis Sci. 2018 Oct; 63(10): 2497-2499. DOI; 10.1007/s10620-018-5136-y
  88. Herfarth, H, Barnes, EL, Valentine, JF, Hanson, J, Higgins, PDR, Isaacs, KL, Jackson, S, Osterman, MT, Anton, K, Ivanova, A, I, Long, MD, Martin, C, Sandler, RS, Abraham, B, Cross, RK, Dryden, G, Fischer, M, Harlan, W, Levy, C, McCabe, R, Polyak, S, Saha, S, Williams, E, Yajnik, V, Hamilton, F, Serrano, J, James, S, Sands, BE and Lewis, JD. Methotrexate is not superior to placebo in maintaining steroid-free remission in ulcerative colitis. Gastro. 2018 Octo; 155(4): 1098-1108. doi: 10.1053/j.gastro.2018.06.046.
  89. Voit, Antanina, Cross, RK, Bellavance, E, and Bafford, AC. Financial toxicity in Crohn’s disease. J Clin Gastroenterol. 2018 Oct 24. Doi: 10.1097/MCG. 0000000000001139.
  90. George, L and Cross, RK. De Jong, et al. Telemedicine for management of inflammatory bowel disease (MyIBDcoach): a pragmatic, multicenter, randomized controlled trial. Lancet. 2017 Sep 2; 390 (10093): 959-968. BMJ Evidenced-Based Medicine. 2019; 24 (1): 37-38. 10.1136/bmjebm-2018-111000.
  91. Cross, RK, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, JK, Collins, JF, Katz, J, Ghazi, L, Patil, SA, Quezada, SM, Russman, K, Riaz, M, Jambaulikar, G, Sivasailam, B, and Quinn, C. A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD). Am J Gastroenterol. 2018 March; 114(3):472-482. doi: 10.1038/s41395-018-0272-8.
  92. Patil, SA, Flasar, MH, Lin, J, Lingohr-Smith, M, Skup, M, Wang, S, Chao, J, and Cross, RK. Reduced Imaging Radiation Exposure Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn’s Disease. Dig Dis Sci. 2019 Jan; 64(1): 60-67. doi: 10.1007/s10620-018-5322-y.
  93. Quezada, SM, McLean, LP, and Cross, RK. Adverse Events in IBD: The 2018 Update. Expert Rev Gastroenterol Hepatol. 2018 Dec; 12(12):1183-1191. doi.org/10.1080/17474124.2018.1545574.
  94. Chudy-Onwugaje, KO, Christian, KE, Farraye, FA, and Cross, RK. A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD. Inflamm Bowel Dis. 2018 Nov 15. https://doi.org/10.1093/ibd/izy327.
  95. Bilgrami, Z, Abutaleb, A, Chudy-Onwugajae, K, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, JK, Ghazi, L, Patil, SA, Quezada, SM, Russman, KM, Quinn, CC, Jambaulikar, G, Beaulieu, DB, Horst, S, and Cross, RK. Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activation and Self-Efficacy. Dig Dis Sci. 2020; 65(1): 96-103. DOI 0.1007/s10620-018-5433-5. Correction to: Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activiation and Self-Efficacy. Dig Dis Sci. 2020; 65(2): 668. 10.1007/s10620-019-05953-4
  96. Quezada, SM and Cross, RK. Cannabis and turmeric as complementary treatments for IBD and other digestive diseases. Curr Gastroenterol Rep. 2019 Jan 11; 21(2):2. Doi: 10.1007/s11894-019-0670-0.
  97. Ko, CW, Singh, S, Feuerstein, JD, Falck-Ytter, C, Falck-Ytter, Y, and Cross, RK. American Gastroenterological Association Institute Guideline on the Management of Mild-to-Moderate Ulcerative Colitis. Gastro. 2019 Feb; 156(3): 748-764. doi: 10.1053/j.gastro.2018.12.009.
  98. Caldera, F, Hayney, MS, and Cross, RK. Using number needed to harm to put the risk of Herpes Zoster from tofacitinib in perspective. Inflamm Bowel Dis. 2019 May; 25(6):955-957. Doi: 10.1093/ibd/izy387.
  99. Schad, CA, Cross, RK, Syed, A, Lonasko, S, and Bafford, AC. Early postoperative anti-TNF therapy does not increase complications following abdominal surgery in patients with Crohn’s disease. Dig Dis Sci. 2019 Jul; 64(7): 1959-1966. Doi: https://doi.org/10.1007/s10620-019-5476-2.
  100. Kinnucan, J, Binion, D, Cross, R, Evans, E, Harlen, K, Matarese, L, Mullins, A, O’Neal, B, Reiss, M, Scott, FI, Weaver, A, and Rosenberg, J. Inflammatory Bowel Disease Care System Referral Pathways. Gastro. 2019 Apr 10. pii: S0016-5085(19)35665-3. doi: 10.1053/j.gastro.2019.03.064
  101. Wong, U and Cross, RK. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease. Expert Opinion On Investigational Drugs. 2019; 28(5): 473-479. DOI: 10.1080/13543784.2019.1597053
  102. Christian, KE, Russman, KM, Rajan, DP, Barr, EA, and Cross, RK. Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post-Hoc Analysis of Clinical Trials. Inflamm Bowel Dis. 2020; 26(1): 125-131. https://doi.org/10.1093/ibd/izz133
  103. Quinn, CC, Chard, S, Roth, EG, Eckert, JK, Russman, KM, and Cross, RK. The Telemedicine for Patients with Inflammatory Bowel Disease (TELE-IBD) Clinical Trial: Qualitative Assessment of Participants’ Perceptions. J Med Internet Res. 2019; 21(6): e14165.
  104. Bhattacharya, S and Cross, RK. Is endoscopic remission in ulcerative colitis still good enough? Inflamm Bowel Dis. 2019; 25(11): 1729-1730. https://doi.org/10.1093/ibd/izz177.
  105. Scott, FI, Rubin, DT, Kugathasan, S, Bousvaros, A, Elson, CO, Newberry, RD, Melmed, GY, Pekow, J, Fleshman, JW, Boyle, BM, Mahadevan, U, Cannon, LM, Long, MD, Cross, RK, Ha, CY, Lasch, KL, Robinson, AM, Rafferty, JF, Lee, JJ, Cowden, DK, Weaver, A, Shtraizent, N, Honig, G, Hurtado-Lorenzo, A, and Heller, CA. Challenges in IBD Research: Pragmatic Clinical Research. Inflamm Bowel Dis. 2019; 25(S2): S40-47.
  106. George, L and Cross, RK. How do we sequence biologic therapies in 2019? Inflamm Bowel Dis. 2020; 26(4): 617-18.
  107. Shen, B, Kochhar, G, Navaneethan, U, Farraye, FA, Schwartz, DA, Iacucci, M, Bernstein, CN,Dryden, G, Cross, RK, Bruining, DH, Kobayashi, T, Lukas, M, Shergill, A, Bortlik, M, Lan, N, Lukas, M, Tang, SJ, Kotze, PG, Kiran, RP, Dulai, PS, El-Hachem, S, Coelho-Prabhu, N, Thakkar, S, Mao, R,Chen, G, Zhang, S, González Suárez, B, Gonzalez Lama, Y, Silverberg, MS, Sandborn, WJ. Practical Guideline on Endoscopic Therapy of Crohn’s Disease Strictures: An Expert Consensus from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol. 2020. Published Online January 16, 2020. https://doi.org/10.1016/
    S2468-1253(19)30366-8.
  108. Haac, BE, Nemirovsky, A, Teeter, W, Geyer, A, Birkett, RT, Cross, RK, Engels, M, Stein, DM, and Bafford, AC. Injury Characteristics and Outcomes of Patients with Inflammatory Bowel Disease after Trauma: A Propensity Score Matched Analysis. Inflamm Bowel Dis. In press.
  109. Cross, RK, Chiorean, M, Vekeman, F, Xiao, Y, Wu, E, Chao, J, and Wang, A. Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. PLOS ONE. In press.
  110. Wong, U and Cross, RK. Are inflammatory bowel disease patients with diabetes mellitus at increased risk for poor outcomes including greater healthcare utilization? Inflamm Bowel Dis. 2020 Jan 16. pii: izz306. doi: 10.1093/ibd/izz306.
  111. Stoleru, G, George, L, Cross, RK, and Wong, U. An unusual presentation of Baker’s cyst rupture in an inflammatory bowel disease patient. Case Reports in Medicine. 2020; 2020 (3140958). https://doi.org/10.1155/2020/3149058
  112. Bafford, A and Cross, RK. Risk of venous thromboembolism in patients with inflammatory bowel disease extends beyond hospitalization. Inflamm Bowel Dis. 29 January 2020. doi.org/10.1093/ibd/izaa003
  113. Kamal, N, Bookwater, A, Foss, R, and Cross, RK. Pyostomatitis vegetans: An unusual oral manifestation of inflammatory bowel diseas. Am J Gastroenterol. In press.
  114. Rossman, L and Cross, RK. Just say no…to the nocebo effect. Inflamm Bowel Dis. 2020; 26(5):660. doi.org/10.1093/ibd/izaa021
  115. Schliep, M, Chudy-Onwugaje, K, Abutaleb, A, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, KT, Ghazi, L, Patil, SA, Quezada, S, Russman, K, Horst, S, Beaulieu, D, Quinn, C, Jambaulikar, G, and Cross, RK. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared to standard care at tertiary referral centers. Crohn’s & Colitis 360. 31 January 2020; 2(1).
  116. Bhattacharya, S and Cross, RK. Therapeutic updates for moderate to severe ulcerative colitis. Dig Med Res. 2020; 3:10. doi: 10.21037/dmr.2020.01.04.
  117. Haac, BE, Rubin, JN, Christian, K, Merechi, F, Wong, U, Cross, RK, Patil, SA and Bafford, AC. Case of invasive metastatic breast cancer mimicking Crohn’s disease. Global Surgery Case Reports. 2020; 1(1):1-3. DOI: 10.31487/j.GSCR.2019.01.04
  118. Bhattacharya, S, Wong, U, and Cross, RK. Telemedicine in the management of inflammatory bowel disease: An update. Smart Homecare Technol Telehealth. 2020; 7:9-17.
  119. Chudy-Onwugaje, K, Mamunes, AP, Schwartz, DA, Horst, S, and Cross, RK. Predictors of high health care utilization in patients with inflammatory bowel disease within 1 year of establishing specialist care. Inflamm Bowel Dis. In press.
  120. Chiorean, M, Afzali, A, Cross, RK, Macaulay, D, Griffith, J, Wang, A, and Garcia-Horton, V. Economic outcomes of inflammatory bowel disease patients switching to a second anti-tumor necrosis factor or vedolizumab. Crohn’s & Colitis 360. In press.
  121. Osterman, MT, Scott, FI, Fogt, FF, Gilroy, ED, Parrott, S, Galanko, J, Cross, R, Moss, A, Herfarth, HH, and Higgins, PDR. Endoscopic and histological assessment, correlation, and relapse in clinically quiescent ulcerative colitis (MARQUEE). Inflamm Bowel Dis. 2020 Mar 14. pii: izaa048. doi: 10.1093/ibd/izaa048.
  122. George, LA, Dominic, MR, and Cross, RK. Integration of telemedicine into clinical practice for inflammatory bowel disease. Curr Opin Gastroenterol. In press.
  123. Syed, N, Tolaymat, M, Brown, SA, Sivasailam, B, and Cross, RK. Proactive drug monitoring is associated with higher persistence to infliximab and adalimumab treatment and lower healthcare utilization compared to reactive and clinical monitoring. Crohn’s & Colitis 360. In press.

Awards and Affiliations

1990-1992        Division III Academic All-American in Football

1991                   Phi Sigma Biology Honorary Society

1993                   Birch Student Athlete Award, Washington and Jefferson College

1993                  Phi Beta Kappa, Washington and Jefferson College

1993                   NCAA Post-Graduate Scholar

1996                   Alpha Omega Alpha, University of Pittsburgh School of Medicine

1997                   Leo H. Kriep Award for Medicine, University of Pittsburgh School of Medicine

2005-2006        Teaching Commendation, Pathophysiology & Therapeutics II, Gastroenterology-Hematopathology Unit

2007                   Best Practices, Colorectal Cancer Collaborative, VA Maryland Health Care System

2007-2009        Recipient, NIH Clinical Loan Repayment Program

2007-2008        Certificate of Teaching Excellence, Functional Systems Small Group Conferences

2010                                  American College of Gastroenterology IBD Abstract Award Recipient

2011                                  Crohn’s and Colitis Foundation, Maryland and Southern Delaware Chapter, Chairman’s Citation Award

2011-2013        Washington DC-Baltimore-Northern Virginia Super Doctors

2012                                  American Gastroenterological Association Fellow

2012                                 American College of Gastroenterology Presidential Poster Recipient

2013-2014        Teacher of the Year, Division of Gastroenterology and Hepatology, University of Maryland, Baltimore

2016                                  Healio Gastroenterology 200 Innovators in Gastroenterology and Hepatology

2017                                  American College of Gastroenterology Presidential Poster Recipient

2018                                  Fellow, American College of Gastroenterology

2018-2019        Baltimore Magazine, Top Doctor, Gastoenterology: Inflammatory Bowel Disease

2018                                  Outstanding Faculty Mentor Award, Department of Medicine, University of Maryland, Baltimore

2019                                  Excellence in Healthcare Award, Crohn’s and Colitis Foundation, Maryland/Southern Delaware Chapter